Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.
AMRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for AMRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amneal Pharmaceuticals Inc ranked in the 84th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 763.67% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Amneal Pharmaceuticals Inc, consider:
17% of the company's capital comes from equity, which is greater than only 5.09% of stocks in our cash flow based forecasting set.
Amneal Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Relative to other stocks in its sector (Healthcare), Amneal Pharmaceuticals Inc has a reliance on debt greater than 95.75% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMRX, try PRSC, ARGX, GTS, HCA, and NHC.